Aldeyra Therapeutics, Inc. · NASDAQ:ALDX
Aldeyra Therapeutics — Investor Presentation (March 2016)
12 slides from Aldeyra Therapeutics's investor presentation, Mar 31, 2016
Slide 1: A Novel Therapy for SSADH: An Aldehyde Trap for an Aldehyde-Mediated Disease
A Novel Therapy for SSADH: An Aldehyde Trap for an Aldehyde-Mediated Disease March 2016 Exhibit 99.1
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements • This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations and expenses, business st
Slide 3: Aldehydes Are Toxic
Aldehydes Aldehydes Are Toxic Destruction of fats, proteins, sugars Formation of toxic metabolites such as -hydroxybutyric acid (GHB) Inflammation
Slide 4: Symptoms of SSADH Deficiency Believed to be Due to Aldehydes
SSA Symptoms of SSADH Deficiency Believed to be Due to Aldehydes Genetic Mutations in SSADH Autism, Cognitive Delay, Decreased Muscle Tone, Seizures Destruction of fats, proteins, sugars Formation of GHB, D-2- hydroxyglutarate (D-2-HG) Inflammation
Slide 5: An Aldehyde Trap Could Diminish the Symptoms of SSADH Deficiency
An Aldehyde Trap Could Diminish the Symptoms of SSADH Deficiency Genetic Mutations in SSADH
Slide 6: Aldehyde Traps: A Novel Therapeutic Approach
Aldeyra’s lead aldehyde trap, NS2, appears to have minimal pharmacology, with no known effects on receptors, enzymes and other proteins. In clinical trials to date, NS2 has been observed to be safe and well-tolerated. Aldeyra is not aware of any similar technology. Aldeyra’s lead aldehyde trap, NS2,
Slide 7: Aldehyde Trap is Proven to Reduce Inflammation in Humans
An Aldehyde Trap is Proven to Reduce Inflammation in Humans Ocular Itching Ocular Tearing Vehicle NS2 Visit 4 Minutes Post-Challenge * * * * * * * *p<0.05 ; p values are subject to change based on quality control analysis Phase IIa Allergic Conjunctivitis Clinical Trial (February, 2016) -1.6 -1.4 -1
Slide 8: Aldeyra is Clinically Testing Aldehyde Traps in Several Diseases
Aldeyra is Clinically Testing Aldehyde Traps in Several Diseases Discovery Formulation Pre-Clinical Phase I Phase II Phase III Allergic Conjunctivitis (NS2 Ocular) Noninfectious Anterior Uveitis (NS2 Ocular) Sjögren-Larsson Syndrome (NS2 Dermatologic) Sjögren-Larsson Syndrome (NS2 Systemic) SSADH De
Slide 9: Our Lead Candidate, NS2, Traps the Toxic Aldehyde in SSADH Deficiency
By trapping SSA, NS2 may prevent the formation of pathologic metabolites that are thought to be responsible for the severe neurological complications of SSADH Deficiency. By trapping SSA, NS2 may prevent the formation of pathologic metabolites that are thought to be responsible for the severe neurol
Slide 10: NS2 May Reduce GHB and D2HG Levels in SSADH KO Mice
NS2 May Reduce GHB and D2HG Levels in SSADH KO Mice Ainslie, Vogel, Cullen, Young, Brady and Gibson, 2015 Washington State University and Aldeyra Therapeutics t test (**p<0.01)
Slide 11: Next Steps in the Development of NS2 for SSADH Deficiency
Next Steps in the Development of NS2 for SSADH Deficiency 1. Generate additional preclinical data supporting the use of NS2 in SSADH patients • Identify endpoints to assess clinical efficacy of NS2 2. Natural History Study • Understand levels of metabolites and clinical endpoints in patients • Use d
Slide 12: Hope for the Future
Hope for the Future “In 2016, we expect to build on our accomplishments from last year by initiating clinical development of aldehyde traps that are administered systemically. We are excited to continue to advance NS2 and other aldehyde traps as a novel therapeutic approach for inflammatory disease
Aldeyra Therapeutics — Investor Presentation (March 2016) on 6ix